Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Key Points
Key Points
- The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
- These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
- This guideline focuses on strategies for controlling the growth of these tumors.
Treatment
...atment...
...General Recommendations for G1–G3 GEP...
....1Selection of initial treatment opti...
...dation 1.2All treatment decisions should...
Recommendation 1.3Patients should be assessed f...
...stemic Therapy for Metastatic G1–G2 G...
...ne Systemic Therapy for G1–G2 GI-NETs...
...mmendation 2.1SSAs (octreotide or l...
...dation 2.2In the less common circumstance of pat...
...er-line Systemic Therapy for G1–G2 GI-NET...
...endation 2.3Peptide receptor radionucl...
Recommendation 2.4Everolimus is recom...
...Therapy for Metastatic G1–G2 Pancreatic NETS (...
...st-line Systemic Therapy for G1–G2...
...ecommendation 3.1SSAs (octreotide or lanreotid...
...endation 3.2Chemotherapy (e.g., capecit...
...tion 3.3Chemotherapy (e.g., CAPTEM), everolimus, o...
...Later-line Systemic Therapy for G1â...
...3.4PRRT for SSTR-positive tumors, chemotherapy...
...stemic Therapy for G3 GEP-NETs...
...4.1The range of systemic options outlined in pr...
...WHO Classification and Grading Criteria for...
...ystemic Therapy for Tumor Control in Wel...
...elieves that cancer clinical trials...